Vanguard Personalized Indexing Management LLC Acquires 7,834 Shares of Organon & Co. (NYSE:OGN)

Vanguard Personalized Indexing Management LLC raised its holdings in Organon & Co. (NYSE:OGN) by 9.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,389 shares of the company’s stock after acquiring an additional 7,834 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Organon & Co. were worth $1,797,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Organon & Co. by 0.6% during the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after buying an additional 192,613 shares in the last quarter. LSV Asset Management raised its holdings in shares of Organon & Co. by 47.3% in the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock valued at $136,843,000 after purchasing an additional 2,121,940 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Organon & Co. by 26.9% in the first quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company’s stock worth $74,563,000 after purchasing an additional 841,518 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Organon & Co. by 1.2% during the first quarter. Principal Financial Group Inc. now owns 2,853,331 shares of the company’s stock worth $53,643,000 after purchasing an additional 35,183 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Organon & Co. by 23.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock valued at $49,843,000 after purchasing an additional 463,216 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Down 3.4 %

Shares of NYSE OGN opened at $19.49 on Friday. The stock has a market capitalization of $5.01 billion, a P/E ratio of 4.77, a PEG ratio of 0.89 and a beta of 0.85. The stock’s fifty day moving average is $21.00 and its 200 day moving average is $20.09. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.04. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm’s revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.31 EPS. Sell-side analysts forecast that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.75%. Organon & Co.’s dividend payout ratio (DPR) is presently 27.38%.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and raised their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.